Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins) Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., Costa, D. B., Tsao, A., Patel, J., Gadgeel, S., Bazhenova, L., Zhu, V. W., West, H., Mekhail, T., Gentzler, R., Nguyen, D., Bunn, V., Jin, S., Feng, Z., Janne, P. A. ELSEVIER. 2020: S815–S816
View details for DOI 10.1016/j.annonc.2020.08.1575
View details for Web of Science ID 000573469101547